20110502
 After Long Pursuit, Teva Wins Cephalon   By Rockoff, Jonathan D, The Wall Street Journal,  May 3, 2011  Starting with a steak dinner near the firms' offices outside Philadelphia, Teva executives finally secured Cephalon's agreement by taking advantage of Cephalon's distaste for a recent $5.7 billion hostile offer from Valeant Pharmaceuticals International Inc. "With this move, we create the critical mass" to establish a sizable, sustainable branded pharmaceutical business, Teva Chief Executive Shlomo Yanai said in an interview.   
